News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
637,830 Results
Type
Article (52564)
Company Profile (176)
Press Release (585090)
Multimedia
Podcasts (77)
Webinars (9)
Section
Business (179326)
Career Advice (2718)
Deals (33042)
Drug Delivery (113)
Drug Development (78930)
Employer Resources (166)
FDA (16464)
Job Trends (15222)
News (316601)
Policy (32350)
Tag
Academia (2842)
Accelerated approval (6)
Adcomms (28)
Allergies (92)
Alliances (46410)
ALS (94)
Alzheimer's disease (1433)
Antibody-drug conjugate (ADC) (144)
Approvals (16430)
Artificial intelligence (277)
Autoimmune disease (27)
Automation (16)
Bankruptcy (341)
Best Places to Work (11573)
BIOSECURE Act (19)
Biosimilars (118)
Biotechnology (122)
Bladder cancer (83)
Brain cancer (31)
Breast cancer (295)
Cancer (2332)
Cardiovascular disease (197)
Career advice (2291)
Career pathing (33)
CAR-T (165)
Cell therapy (450)
Cervical cancer (19)
Clinical research (64443)
Collaboration (871)
Company closure (1)
Compensation (249)
Complete response letters (30)
COVID-19 (2828)
CRISPR (45)
C-suite (249)
Cystic fibrosis (107)
Data (2203)
Decentralized trials (2)
Denatured (19)
Depression (54)
Diabetes (286)
Diagnostics (6428)
Digital health (19)
Diversity (3)
Diversity, equity & inclusion (38)
Drug discovery (123)
Drug pricing (114)
Drug shortages (29)
Duchenne muscular dystrophy (100)
Earnings (67196)
Editorial (45)
Employer branding (22)
Employer resources (146)
Events (85961)
Executive appointments (743)
FDA (17746)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (759)
Gene editing (112)
Generative AI (25)
Gene therapy (333)
GLP-1 (815)
Government (4740)
Grass and pollen (6)
Guidances (67)
Healthcare (18742)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (140)
Indications (29)
Infectious disease (2985)
Inflammatory bowel disease (140)
Inflation Reduction Act (8)
Influenza (55)
Intellectual property (100)
Interviews (509)
IPO (14720)
IRA (42)
Job creations (4033)
Job search strategy (1911)
Kidney cancer (11)
Labor market (32)
Layoffs (533)
Leadership (24)
Legal (7347)
Liver cancer (81)
Lung cancer (333)
Lymphoma (155)
Machine learning (7)
Management (59)
Manufacturing (314)
MASH (69)
Medical device (13273)
Medtech (13278)
Mergers & acquisitions (18816)
Metabolic disorders (753)
Multiple sclerosis (85)
NASH (21)
Neurodegenerative disease (110)
Neuropsychiatric disorders (31)
Neuroscience (2011)
NextGen: Class of 2025 (6761)
Non-profit (4852)
Now hiring (32)
Obesity (408)
Opinion (246)
Ovarian cancer (76)
Pain (95)
Pancreatic cancer (82)
Parkinson's disease (155)
Partnered (20)
Patents (223)
Patient recruitment (111)
Peanut (50)
People (54379)
Pharmaceutical (31)
Pharmacy benefit managers (20)
Phase I (20030)
Phase II (28146)
Phase III (21587)
Pipeline (1228)
Policy (157)
Postmarket research (2562)
Preclinical (7813)
Press Release (63)
Prostate cancer (108)
Psychedelics (34)
Radiopharmaceuticals (231)
Rare diseases (407)
Real estate (5691)
Recruiting (69)
Regulatory (22465)
Reports (35)
Research institute (2508)
Resumes & cover letters (414)
Rett syndrome (5)
RNA editing (4)
RSV (50)
Schizophrenia (78)
Series A (137)
Series B (88)
Service/supplier (9)
Sickle cell disease (56)
Special edition (16)
Spinal muscular atrophy (156)
Sponsored (26)
Startups (3566)
State (1)
Stomach cancer (15)
Supply chain (72)
Tariffs (43)
The Weekly (56)
Vaccines (799)
Venture capitalists (43)
Weight loss (284)
Women's health (31)
Worklife (20)
Date
Today (7)
Last 7 days (809)
Last 30 days (2355)
Last 365 days (30687)
2025 (10114)
2024 (33073)
2023 (37837)
2022 (48493)
2021 (52902)
2020 (52608)
2019 (46512)
2018 (35736)
2017 (32329)
2016 (31337)
2015 (35415)
2014 (27071)
2013 (22252)
2012 (23986)
2011 (24759)
2010 (22069)
Location
Africa (927)
Alabama (55)
Alaska (7)
Arizona (174)
Arkansas (14)
Asia (37966)
Australia (6550)
California (5865)
Canada (1734)
China (503)
Colorado (262)
Connecticut (259)
Delaware (119)
Europe (87339)
Florida (810)
Georgia (187)
Hawaii (1)
Idaho (59)
Illinois (523)
India (26)
Indiana (299)
Iowa (9)
Japan (154)
Kansas (96)
Kentucky (26)
Louisiana (11)
Maine (68)
Maryland (833)
Massachusetts (3854)
Michigan (213)
Minnesota (354)
Mississippi (2)
Missouri (84)
Montana (26)
Nebraska (25)
Nevada (56)
New Hampshire (69)
New Jersey (1532)
New Mexico (30)
New York (1606)
North Carolina (920)
North Dakota (9)
Northern California (2503)
Ohio (187)
Oklahoma (13)
Oregon (34)
Pennsylvania (1193)
Puerto Rico (12)
Rhode Island (30)
South America (1283)
South Carolina (21)
South Dakota (1)
Southern California (2261)
Tennessee (98)
Texas (801)
United States (21129)
Utah (190)
Virginia (143)
Washington D.C. (61)
Washington State (522)
West Virginia (3)
Wisconsin (52)
637,830 Results for "selexis sa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO
KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, today announced the appointment of J.D. Mowery as Chief Executive Officer (CEO).
April 17, 2023
·
3 min read
Press Releases
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
May 1, 2025
·
6 min read
Deals
JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as one Organization, Providing Seamless Experience for Partners
JSR Life Sciences today announced that KBI Biopharma, Inc. (KBI) and Selexis SA are consolidating as one organization under the KBI Biopharma name to accelerate innovation and growth for its global biopharma customers.
May 31, 2023
·
4 min read
Business
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as the companies’ Chief Business Officer.
October 31, 2022
·
3 min read
Business
KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing Facility in Geneva, Switzerland
KBI Biopharma SA and Selexis SA, both JSR Life Sciences companies, announced that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Switzerland.
June 14, 2022
·
3 min read
Press Releases
LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7
February 17, 2025
·
4 min read
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
RELIEF THERAPEUTICS Holding SA announces the results of its annual general meeting (AGM) of shareholders, which took place in Geneva today.
June 27, 2024
·
3 min read
Press Releases
Acquisition of Ovizio Imaging Systems SA
October 17, 2024
·
1 min read
Deals
Stryker completes acquisition of SERF SAS
Stryker (NYSE: SYK), a leading global medical technology company, announced today that it has completed the previously announced acquisition of SERF SAS, a France -based joint replacement company, from Menix.
March 21, 2024
·
4 min read
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA announces the results of the extraordinary general meeting of shareholders, which took place in Geneva , Friday, April 26, 2024.
April 26, 2024
·
4 min read
1 of 63,783
Next
